NASDAQ:NVCR
NovoCure Ltd
NovoCure Ltd's revenue grew 8.3% in fiscal 2025 to $655.4M while operating margin rose to −23.5%. Free cash flow was −$75.7M, −11.5% of revenue, and the diluted share count rose 3.4%.Summary generated from NovoCure Ltd's SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$655.4M
Revenue growth+8.3%
Revenue, 5-yr CAGR+5.8%
Gross margin74.5%
Operating margin−23.5%
Net margin−20.8%
ROIC−33.0%
Return on equity−38.9%
Debt / equity0.57
Free cash flow−$75.7M
FCF margin−11.5%
Share count change+3.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 535 | 538 | 509 | 605 | 655 |
| Operating income | −44 | −90 | −233 | −170 | −154 |
| Net income | −58 | −93 | −207 | −169 | −136 |
| Free cash flow | 59 | 9 | −100 | −69 | −76 |
Recent filings
- 8-KRegulation FD disclosure
Oct 1, 2026 - 8-KDirector or officer change
Sep 9, 2026 - 8-KOther events
Sep 1, 2026 - 8-KResults of operations and financial condition
Jul 23, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 23, 2026 - 4Insider transaction report
Jul 1, 2026 - 4Insider transaction report
Jul 1, 2026 - 8-KRegulation FD disclosure
Jun 30, 2026